Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial

By sjmartinez • May 15, 2024

Corado KC, Chew KW, Giganti MJ, Mu Y, Fletcher CV, Currier JS, Daar ES, Wohl DA, Li JZ, Moser CB, Ritz J, Javan AC, Neytman G, Caskey M, Hughes MD, Smith DM, Eron JJ; ACTIV-2/A5401 Study Team. Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial. Pathog Immun. 2024 May 6;9(1):138-155. doi: 10.20411/pai.v9i1.660. PMID: 38746756; PMCID: PMC11093219.

Tags: covid-19, Harbor UCLA, Infectious Diseases, Monoclonal antibodies, outpatient treatment, Publications, SARS-CoV-2, subcutaneous

Opportunistic AI-derived adiposity measures from coronary artery calcium scans predict new-onset type 2 diabetes in adults without obesity or hyperglycemia: insights from the AI-CVD study within MESA

Naghavi M, Azimi A, Atlas K, Reeves AP, Zhang C, Wasserthal J, Mirjalili SR, Mozafarybazargany M, Hashemi A, Atlas T, Henschke CI, Yankelevitz DF, Mechanick[...]

Environmental and human health impact of contact precaution use for methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus in Los Angeles County

Lee PS, OYong K, Shah AN, Thiel C, LeBrun M, Miller LG, Rubin Z. Environmental and human health impact of contact precaution use for methicillin-resistant Staphylococcus[...]

SPIROMICS HF: Rationale, Design, and Reproducibility of Measures

Barr RG, Lima JAC, Prince MR, Ambale Venkatesh B, Abraham T, Agarwal PP, Arora G, Balasubramanian A, Barjaktarevic I, Bello NA, Bluemke DA, Budoff MJ,[...]